1. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, and Low PA (1998): A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology, 51, 120–124.
2. Kolossa N, Shutzenberger WG, Wiener H and Krivnek P (1979): Plasma levels of the prodrug midodrine and its active metabolite in comparison with the alpha-mimetic action in dogs. Arch. Int. Pharmacodyn., 96, 120–124.
3. Grobecker Von H, Kees F, Linden M, Schrader E and Welte S (1987): Untersuchungen zur Bioverfugbarkeit von Midodrin und Éω-2,5-Dimethoxyphenyl-Éǵa-aminoethanol-hydrochlorid. Arzneim.-Forsch./Drug Res., 37, 447–450.
4. 4.Tsutsui S, Suwa T, Masuda N, Minagawa T, Sano M, Tamaya R and Tsuchida K (1987): Midodrine-no-Tainaidotai. Kiso-to-Rinsho, 21, 549–561.
5. Posch W and Lindner W (1989): Quantification of Midodrine and its Active Metabolite in Plasma using a High Performance Liquid Chromatography Column Switching Technique. Biomed., Chromatogr., 3, 153–156.